Alira Health

Alira Health

We Announce our Role as a Transaction Advisor to Daiichi Sankyo on the Sale of LOPRESSOR®, ICAZ®, and MIOREL® to SIT Laboratorio Farmaceutico (DESMA HC Group)

SIT Laboratorio Farmaceutico a company of DESMA HC Group Acquires LOPRESSOR®, ICAZ® and MIOREL® from Daiichi Sankyo France
Published on:
July 30, 2020

Paris, Milan – (30 July 2020) Daiichi Sankyo France /(hereafter, Daiichi Sankyo) and SIT Laboratorio Farmaceutico (DESMA HC Group) are pleased to announce the acquisition of LOPRESSOR®, ICAZ® and MIOREL® by SIT Laboratorio Farmaceutico from Daiichi Sankyo France, effective from 30th June 2020.
LOPRESSOR® and ICAZ® are oral treatments of essential hypertension. LOPRESSOR® is a beta blocker indicated in treatment of hypertension. ICAZ® is a calcic inhibitor indicated in the treatment of essential hypertension. MIOREL® is a colchicine derivative muscle relaxant, adjuvant in treatment of painful muscle contractures.
This acquisition represents a significant elevation for DESMA HC Group in the France Market and Export Market (African Countries) in terms of both size and value.

Lamberto Pedrotti, Desma’s Managing Director, comments, “The acquisition of LOPRESSOR®, ICAZ® and MIOREL® has a key effect in the future of our company; it will allow us to integrate our portfolio and significantly strengthen our presence in France. Moreover, DESMA HC Group intends to uplift and enhance its export activity. International acquisitions of mature branded medicines is at the core of our business. DESMA HC Group is now present in five continents and more than 40 countries including Asia, Oceania, the Americas, and mainland Europe.”
Benoit Escoffier, Daiichi Sankyo France’s General Manager, comments, “We are very proud of what we have achieved in a very collaborative way with SIT Laboratorio Farmaceutico. This step will allow us to optimize the allocation of resources to focus on oncology in the French market and realize our vision of becoming a world-leading oncology company.”

Silvia Lunati, Group CS Director, further comments, “This acquisition has been conducted with great flexibility and ability both in DESMA HC Group and Daiichi Sankyo, and has confirmed the skill of DESMA HC Group in negotiating and closing acquisitions of mature brands. The team is now focused on working in partnership with Daiichi Sankyo on transitioning the products across all the involved markets. DESMA HC Group also confirms the objective of maintaining the actual distribution network to ensure great business continuity.”

Alira Health acted as an advisor to Daiichi Sankyo.

DESMA HC Group is a family-owned international pharmaceutical company, based in Italy since 1927, and today is an international pharmaceutical group with 90 years of experience and a recent history of prestigious acquisitions and global expansion. DESMA HC Group is a reliable preferred acquirer for pharma businesses choosing to divest their “mature,” “established” or “tail” off-patent branded medicines.
In our Manufacturing plants, we continue the high-quality manufacturing and management of the medicines, aspiring to breathe new life into medicines, investing in them to renew the lifecycle and give new stability and sustainability over the long-term.

Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical therapies to improve standards of care and address diversified, unmet medical needs of people globally by leveraging our world-class science and technology. With more than 100 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 15,000 employees around the world draw upon a rich legacy of innovation and a robust pipeline of promising new medicines to help people. In addition to a strong portfolio of medicines for cardiovascular diseases, under the Group’s 2025 Vision to become a “Global Pharma Innovator with Competitive Advantage in Oncology,” Daiichi Sankyo is primarily focused on providing novel therapies in oncology, as well as other research areas centered around rare diseases and immune disorders. For more information, please visit:

Read on PR Newswire here.

To learn more about Alira Health

Contact us

Related news

Events October 6, 2022
The MedTech Conference 2022
We are pleased to share that we will be joining the MedTech Conference 2022 as sponsors and speakers! This year’s edition will have more than 100 sessions focusing on today’s hot topics.
M&A MedTech Regulatory
News January 13, 2022
Alira Health Secures an Additional $40M in Funding, Led by Creadev
We announced today the closing of an equity financing in which it raised gross proceeds of US$40 million. The financing was provided by key existing investors Creadev, an evergreen(...)
M&A MedTech Pharma Press Release
Articles August 3, 2021
What You Should Know Before Choosing a Healthcare Transaction Advisory Firm
Key questions to ask to help ensure that your next transaction advisory firm partnership is best positioned to achieve your goals.
News April 12, 2021
Alira Health Strengthens Growth Strategy with $35M Funding, led by Creadev
Alira Health strengthens its growth strategy with a $35M funding, led by Creadev.
M&A MedTech Pharma
News December 20, 2020
We Announce our role as Strategic Advisor to Mérieux Equity Partners and Mérieux Participations 3 for Entering the Capital of CTRS
We are pleased to announce our role as strategic advisor to Mérieux Equity Partners as they join the Series A financing round of Cell-Easy, through Mérieux’s newly established venture fund, OMX.
M&A Pharma
News November 29, 2020
Alira Health as Strategic Advisor to Benvic in Acquisition Luc & Bel
We are proud to announce our role as strategic advisor to Benvic in the acquisition of Luc & Bel.
Reports November 1, 2020
Five Key Success Factors for Managing Transactions in Full Virtual Mode
It is no secret that the COVID-19 pandemic has presented new challenges for businesses, and virtual has become the ‘new normal’, including for transactions.
Welcome to Alira Health. This site is best viewed in Chrome, Microsoft Edge, or Firefox.